Last September, another obesity-focused biotech, BioAge, completed an upsized IPO that raised $198 million, after the number of shares on offer was hiked by 40%. Metsera's lead asset is MET-097i ...

Following a flurry of activity in early 2025, the IPO scene has cooled in the wake of President Trump’s economic tremors.

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Metsera (MTSR), which is developing ultra-long ... More on Renaissance Capital Greenwich Funds - Renaissance IPO ETF IPO: Favorable Capital Markets In 2025 Not Yet A Tailwind (Rating Downgrade ...

When considering what names to put on your watch list, look for stocks with an 80 or higher RS Rating. MetseraMTSR just cleared that benchmark with an upgrade from 66 to 84. Please watch the video at ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

It was the highest total IPO value raised since 2021, with the rebound driven by US Federal Reserve interest rate cuts. The uptick continued into 2025, with Sionna joined by Maze Therapeutics and ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a ...

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of ...

MET-097i is Metsera’s fully biased, monthly, ultra-long acting GLP-1 receptor agonist. Metsera will present clinical data from MET-097i’s Phase 1/2 clinical trial in two presentations ...